Virtual event | 2 July 2024

15:00-16:30 CEST | 14:00-15:30 BST 

The Estimands Implementation Working Group (EIWG) and PSI are hosting a new webinar to showcase the application of the estimand framework in a Phase 3 Alzheimer's disease trial.

GRADUATE I(NCT03444870) and GRADUATE II (NCT03443973) were two global, Phase III, randomized, placebo-controlled trials assessing the efficacy and safety of gantenerumab in early Alzheimer's disease. The GRADUATE studies were among the first pivotal trials in Alzheimer's Disease to adopt the estimand framework and to conduct a primary analysis which is fully aligned with the targeted estimand.

In this webinar, experts will review the key elements of the estimand framework through the experience of the Graduate study team. They will explain how the Graduate study team interpreted the estimand framework and used its elements to cover the primary clinical question of interest. Additionally, the webinar will cover the challenges encountered and the solutions implemented during the studies.

Speakers:
- Chair: Marcel Wolbers (Roche)
- Rachid Abbas (Roche)
- Angeliki Thanasopoulou (Roche) 

You can register here.